Research programme: combination therapies - Angiotech/CombinatoRx

Drug Profile

Research programme: combination therapies - Angiotech/CombinatoRx

Latest Information Update: 13 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Angiotech Pharmaceuticals; CombinatoRx
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Joint disorders; Peripheral arterial disorders; Vascular disorders; Vascular restenosis

Most Recent Events

  • 08 Jul 2009 Preclinical development is ongoing in USA and Canada
  • 13 Jun 2007 CombinatoRx and Angiotech have extended their research and development collaboration
  • 03 Oct 2005 Preclinical trials in Joint disorders in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top